Dear Editor,

Since December 2019, a coronavirus disease-2019 (COVID-19) was first reported in Wuhan, China, which was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and expeditiously spread to countries worldwide with massive mortality \[[@CR1]\]. The response of lymphocytes in COVID-19 is characterized by a phenomenon of lymphopenia and hypercytokinemia, and is correlated with disease severity and prognosis \[[@CR2]\]. Besides, interleukin-6 (IL-6) may be the key cytokine leading to inflammatory storm in COVID-19 \[[@CR3]\]. Hence, we develop a simplified immune-dysregulation index---the level of IL-6 to lymphocytes count ratio---to define the immune-dysregulation in COVID-19. We aimed to evaluate the predictive value of IL-6/lymphocyte in patients with COVID-19.

We conducted a retrospective study based on patients with confirmed diagnosis of COVID-19 admitted to the intensive care units in Tongji Hospital. The inclusion and exclusion criteria were presented in the online supplement. IL-6 (pg/ml) and lymphocytes count (10^6^/ml) within the first day after hospital admission were collected. IL-6/lymphocyte was calculated. We used the highest ratio if a variable was recorded more than once. The primary outcome was 28-day mortality. Multivariate regression was selected to characterize the association between IL-6, lymphocyte, IL-6/lymphocyte and 28-day mortality, respectively (description in the online supplement), we then model the nonlinear relationship between IL-6/lymphocyte and 28-day mortality using splines, and the predictive value of IL-6/lymphocyte, IL-6 and lymphocytes for 28-day mortality was compared according to receiver operating characteristic (ROC) curves, net reclassification improvement (NRI) and integrated discrimination improvement (IDI). We also attempt to stratified patients through the IL-6/lymphocyte. The study was approved by Tongji Hospital Ethics Committee.

A total of 172 patients were included in our study (description in the online supplement). Overall 28- day mortality was 50.5%. Baseline characteristics between survivors and non-survivors are presented in eTable 1. Survivors had a higher lymphocytes count (0.94 (0.73--1.28) vs. 0.53 (0.38--0.74); *p* \< 0.001) and a lower IL-6 (7.1 (2--21.6) vs. 61.1 (33.4--137.4); *p* \< 0.001) compared non-survivors. Statistical analysis demonstrated that lymphocyte is negatively correlated with IL-6 (*R* = − 0.26; *p* \< 0.001) (eFig. 1). IL-6/lymphocyte was significantly higher in non-survivors than that in survivors (125.5 (56.9--267.4) vs. 8.3 (2.1--23.4); *p* \< 0.001). The logistic regression analyses showed a significantly association between lymphocyte (OR 0.03; 95% CI 0.01--0.17; *p* \< 0.001), IL-6 (OR 1.03; 95% CI 1.01--1.05; *p* \< 0.001); IL-6/lymphocyte (OR 1.05; 95% CI 1.03--1.08; *p* \< 0.001) and 28-day mortality, respectively (eTables 2, 3 and 4). The nonlinear relationship between IL-6/lymphocyte and 28-day mortality is shown in Fig. [1](#Fig1){ref-type="fig"}a.Fig. 1**a** Relationship between IL-6/lymphocyte and 28-day mortality for intensive care patients with COVID-19 using splines. Overlying red is fitted linear splines with 95% CI. **b** ROC curve analysis and comparison of the AUCs for IL-6/lymphocyte, IL-6 and lymphocytes in COVID-19. **c** Stratified mortality of groups based on the cutoff value of IL-6/lymphocyte in COVID-19. Bars show the percent of patients who died and 95% CI. COVID-19: coronavirus disease-2019; ROC: receiver operating characteristic; AUC: area under the curve

Figure [1](#Fig1){ref-type="fig"}b indicates that IL-6/lymphocyte had a higher area under the curve (AUC) (0.93 (95% CI 0.9--0.96)) than IL-6 (0.88 (95% CI 0.83--0.92); *p* \< 0.001) and lymphocytes (0.81 (95% CI 0.75--0.87); *p* \< 0.001). Compared with IL-6, IL-6/lymphocyte resulted in an additive NRI of 22.2% (95% CI: 9.7--34.7%; *p* \< 0.001), and an IDI of 11.8% (95% CI: 8--15.6%; *p* \< 0.001); compared with lymphocyte, IL-6/lymphocyte resulted in an additive NRI of 36.5% (95% CI 17.2--55.8%; *p* \< 0.001) and an IDI of 20.2% (95% CI 11.8--28.6%; *p* \< 0.001). According to the value of IL-6/lymphocyte, we divided patient into three groups: Group I (\< 15); Group II (15--50); Group III (\> 50), and the Group III had the highest 28-day mortality (Fig. [1](#Fig1){ref-type="fig"}c).

The degree of lymphopenia and the increase in inflammatory cytokine---especially IL-6---were associated with poor outcome in patients with COVID-19 \[[@CR4]\]. Our study developed a novel marker to represent immune-dysregulation and concluded that IL-6/lymphocyte had an improved predictive value compared to IL-6 and lymphocytes alone. Additionally, IL-6/lymphocyte showed a potential value to identify high-risk patients who needed more timely therapy at the early phase of COVID-19. The limitations of study are the incomplete assessment of immune-dysregulation and a single-center experience. Further researches are needed to compare IL-6/lymphocyte and other immunological indicators, as well as the dynamic change of IL-6/lymphocyte.
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